FDA approves high-tech screening device to help spot early-stage skin cancer

FDA approves high-tech screening device to help spot early-stage skin cancer

November 2nd, 2011 // 12:14 pm @ jmpickett

Dermatologists will soon get some high-tech help deciding which suspicious-looking moles should be removed and checked for melanoma, the deadliest form of skin cancer.

The Food and Drug Administration on Wednesday approved a first-of-its-kind device, called MelaFind, that makes detailed, digital images of skin growths and uses a computer to analyze them for signs of cancer, offering a sort of second opinion to doctors. The device is approved only for dermatologists and only for use on growths that don’t have obvious signs of cancer but still have one or two worrisome traits.

0

Comments

Weigh In
Corrections?

inShare

The hope is to find more melanomas sooner. Nearly all patients diagnosed with early-stage melanoma can be treated and cured, but 85 percent of patients with late-stage melanoma die from it within five years.

More than 70,000 people in the U.S. will be diagnosed with melanoma this year, and 16 percent are diagnosed only after the disease has spread to other parts of the body, according to estimates from the National Institutes of Health.

To diagnose the disease, doctors decide which moles to remove and biopsy using an entirely visual set of guidelines involving size, shape and color. Most dermatologists easily spot late-stage lesions that have obvious signs of cancer, including irregular edges, uneven color and a width greater than 6 millimeters. But many others are tough calls.

“Every day patients come in with 20 moles on their back and the dilemma is, which ones are suspicious and need to be biopsied?” said Dr. David Pariser, former president of the American Academy of Dermatology. “The diagnosis of melanoma is the most serious one a dermatologist makes, and we have sleepless nights worrying about it,” said Pariser, who consulted for the device’s maker, Mela Sciences Inc. of Irvington, N.Y., on its presentation to FDA.

The device’s handheld attachment, about the size of a blow dryer, emits light that penetrates below the surface of the skin, taking multicolored images that reflect the depth and shape of skin growths. A computer compares these to a database of 10,000 archived images and recommends whether a biopsy should be done.

In a company-sponsored study published last year involving around 1,300 patients, some with multiple growths, doctors reported that MelaFind correctly suggested biopsies on 125 of 127 melanomas that doctors had removed. However, the device did not raise an alarm about non-melanoma growths only about 10 percent of the time; that was still better than doctors in the study who correctly ruled out melanoma in less than 4 percent of such cases, on average. The study was published in the Archives of Dermatology.

The company’s study was not intended to show that screening with the device saves lives, only that it can help improve a doctor’s ability to spot melanoma.

For now, experts say MelaFind will help dermatologists make better decisions on which moles to remove.

“There is no such thing as 100 percent certainty in medicine,” said Dr. George Elias, a melanoma expert at Georgetown’s Lombardi Comprehensive Cancer Center who had no ties to the company or the device. “Ultimately it’s the responsibility of the dermatologist to use his clinical judgment to make the best decision. This machine is there to help him, not replace him.”